Suppr超能文献

《百万女性研究》发表后荷兰激素替代疗法处方的显著变化:一项随访研究

Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up study.

作者信息

Faber Adrianne, Bouvy Marcel L, Loskamp Linda, van de Berg Paul B, Egberts Toine C G, de Jong-van den Berg Lolkje T W

机构信息

Groningen University Institute for Drug Exploration, University of Groningen, Department of Social Pharmacy, Pharmacoepidemiology and Pharmacotherapy, Groningen, The Netherlands.

出版信息

Br J Clin Pharmacol. 2005 Dec;60(6):641-7. doi: 10.1111/j.1365-2125.2005.02502.x.

Abstract

AIMS

To estimate the diffusion of new safety information concerning postmenopausal hormonal replacement therapy (HRT) into prescribing practice in The Netherlands and to assess the impact of revised guidelines on the long-term treatment of HRT.

DESIGN

Cross-sectional study.

SETTING

Community pharmacy dispensing data from a population of approximately 450,000 patients in the northern and eastern part of The Netherlands.

POPULATION

Women aged 45-69 years to whom at least one HRT prescription was dispensed between 1 January 2000 and 1 January 2004.

MAIN OUTCOME MEASURES

Annual and quarter prevalences of HRT and the proportion of new HRT users, switchers and continuous HRT users per quarter.

RESULTS

The prevalence of HRT prescribing decreased significantly from 107/1000 [95% confidence interval (CI) 104, 110] in 2000 to 87/1000 (95% CI 84, 89) in 2003. The decreasing prevalence was especially evident among the younger age groups and was most pronounced among users of oestrogen/progestagen combinations. The publication of the Women Health Initiative Study (WHI) was followed by a modest decrease in prescribing of HRT, whereas prescribing of HRT declined dramatically after publication of the Million Women Study (MWS) in August 2003. Among the continuous HRT users in the 4th quarter of 2002, 55% used HRT longer than 3 years. This percentage was 53 in the 4th quarter of 2003.

CONCLUSIONS

In contrast to the release of the WHI study results, publication of the MWS was followed by a dramatic fall in prescribing of HRT in The Netherlands. Despite the new recommendation that long-term HRT use should be discouraged, the proportion of long-term users did not change after the publication of the MWS.

摘要

目的

评估有关绝经后激素替代疗法(HRT)的新安全信息在荷兰处方实践中的传播情况,并评估修订指南对HRT长期治疗的影响。

设计

横断面研究。

背景

来自荷兰北部和东部约45万患者群体的社区药房配药数据。

研究对象

2000年1月1日至2004年1月1日期间至少开具过一张HRT处方的45至69岁女性。

主要观察指标

HRT的年度和季度患病率,以及每季度新HRT使用者、转换使用者和持续HRT使用者的比例。

结果

HRT处方患病率从2000年的107/1000[95%置信区间(CI)104,110]显著降至2003年的87/1000(95%CI 84,89)。患病率下降在较年轻年龄组中尤为明显,在雌激素/孕激素联合使用者中最为显著。《妇女健康倡议研究》(WHI)发表后,HRT处方量略有下降,而在2003年8月《百万妇女研究》(MWS)发表后,HRT处方量大幅下降。在2002年第四季度的持续HRT使用者中,55%使用HRT超过3年。2003年第四季度这一比例为53%。

结论

与WHI研究结果发布情况不同,MWS发表后,荷兰HRT处方量大幅下降。尽管有新建议不鼓励长期使用HRT,但MWS发表后长期使用者的比例并未改变。

相似文献

2
HRT use in 2001 and 2004 in The Netherlands--a world of difference.
Maturitas. 2006 May 20;54(2):193-7. doi: 10.1016/j.maturitas.2005.10.010.
5
[Utilization of hormone replacement therapy in Spain: Trends in the period 2000-2014].
Med Clin (Barc). 2016 Oct 7;147(7):287-92. doi: 10.1016/j.medcli.2016.05.023. Epub 2016 Aug 8.
6
Treatment of menopausal symptoms in family medicine settings following the Women's Health Initiative findings.
J Am Board Fam Med. 2006 Mar-Apr;19(2):122-31. doi: 10.3122/jabfm.19.2.122.
7
Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005.
Eur J Clin Pharmacol. 2007 Sep;63(9):843-9. doi: 10.1007/s00228-007-0320-6. Epub 2007 Jun 28.
8
The relevance of the Women's Health Initiative results on combined hormone replacement therapy in clinical practice.
J Obstet Gynaecol Can. 2002 Sep;24(9):711-5. doi: 10.1016/s1701-2163(16)30326-7.
9
The impact of the Women's Health Initiative on hormone replacement therapy in a Medicaid program.
J Womens Health (Larchmt). 2004 Nov;13(9):986-92. doi: 10.1089/jwh.2004.13.986.
10
The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus.
Br J Clin Pharmacol. 2006 Dec;62(6):660-5. doi: 10.1111/j.1365-2125.2006.02711.x. Epub 2006 Jun 23.

引用本文的文献

4
Current and emerging therapies for the treatment of osteoporosis.
J Exp Pharmacol. 2010 Aug 27;2:121-34. doi: 10.2147/JEP.S7823. eCollection 2010.
6
Is transdermal menopausal hormone therapy a safer option than oral therapy?
CMAJ. 2013 Apr 16;185(7):549-50. doi: 10.1503/cmaj.130004. Epub 2013 Mar 18.
7
Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions.
Endocrinol Metab Clin North Am. 2011 Sep;40(3):509-18, viii. doi: 10.1016/j.ecl.2011.05.006. Epub 2011 Jul 12.
8
Recent Trends in Breast Cancer Incidence and Mortality in Germany.
Breast Care (Basel). 2009;4(2):75-80. doi: 10.1159/000211526. Epub 2009 Apr 24.
9
Mind-body therapies for menopausal symptoms: a systematic review.
Maturitas. 2010 Jun;66(2):135-49. doi: 10.1016/j.maturitas.2010.01.016. Epub 2010 Feb 18.
10
Exogenous and endogenous hormones and breast cancer.
Best Pract Res Clin Endocrinol Metab. 2008 Aug;22(4):573-85. doi: 10.1016/j.beem.2008.08.001.

本文引用的文献

1
Impact of safety warnings on drug utilization: marketplace life span of cisapride and troglitazone.
Pharmacotherapy. 2004 Aug;24(8):978-86. doi: 10.1592/phco.24.11.978.36136.
4
Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results.
Ann Intern Med. 2004 Feb 3;140(3):184-8. doi: 10.7326/0003-4819-140-3-200402030-00009.
8
Breast cancer and hormone-replacement therapy in the Million Women Study.
Lancet. 2003 Aug 9;362(9382):419-27. doi: 10.1016/s0140-6736(03)14065-2.
9
Breast cancer and hormone-replacement therapy: up to general practice to pick up the pieces.
Lancet. 2003 Aug 9;362(9382):414-5. doi: 10.1016/S0140-6736(03)14095-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验